Observational study of inclisiran effectiveness in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 202...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2023-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5687 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839576563791691776 |
|---|---|
| author | A. I. Sapina Yu. Yu. Varlamova M. G. Papyrina A. S. Bezymyannyy E. Yu. Vasilyeva |
| author_facet | A. I. Sapina Yu. Yu. Varlamova M. G. Papyrina A. S. Bezymyannyy E. Yu. Vasilyeva |
| author_sort | A. I. Sapina |
| collection | DOAJ |
| description | Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 2023.Material and methods. For the observational study, 50 patients were included in the inclisiran therapy group and 30 patients in the control group (patients with ASCVD receiving PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29)). All study participants had their anamnestic data analyzed, and initially underwent electrocardiography, echocardiography, extracranial and lower limb Doppler ultrasound, and laboratory tests (complete blood count, biochemical blood tests, lipid profile). Three medical organizations of the Moscow State Healthcare System participate in the study.Results. Interim data are presented to evaluate the effectiveness of PCSK9 targeted therapy in patients with ASCVD, obtained 3 months from the study start. The comparison groups were comparable in main clinical characteristics. When analyzing the lipid-lowering effect of inclisiran in the examined patients with ASCVD, LDL-C level significantly decreased from 2,53±0,10 mmol/l to 110±0,08 mmol/l (by 56,5%), p<0,0001, while the target LDL-C level <1,4 mmol/l was achieved by 77,5% of the subjects. Analysis of the lipid-lowering effect of alirocumab/evolocumab showed a significant LDL-C decrease from 2,48±0,16 mmol/l to 1,07±0,11 mmol/l (by 56,8%), p<0,0001.Conclusion. The use of PCSK9 targeted therapy (alirocumab or inclisiran or evolocumab) in patients with ASCVD in Moscow make it possible to achieve target LDL-C levels, which are indicated in clinical guidelines, by 3 months. |
| format | Article |
| id | doaj-art-db88a5b976c64fde8b9173d30faba94f |
| institution | Matheson Library |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2023-12-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-db88a5b976c64fde8b9173d30faba94f2025-08-04T13:00:31Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202023-12-01281210.15829/1560-4071-2023-56873963Observational study of inclisiran effectiveness in Moscow healthcareA. I. Sapina0Yu. Yu. Varlamova1M. G. Papyrina2A. S. Bezymyannyy3E. Yu. Vasilyeva4I.V. Davydovsky City Clinical Hospital; Research Institute for Healthcare and Medical Management of Moscow Healthcare DepartmentDiagnostic and Clinical Center № 1City Clinic № 46Directorate for coordination of activities of medical organizations of the Department of Health of the city of MoscowI.V. Davydovsky City Clinical Hospital; A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian FederationAim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 2023.Material and methods. For the observational study, 50 patients were included in the inclisiran therapy group and 30 patients in the control group (patients with ASCVD receiving PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29)). All study participants had their anamnestic data analyzed, and initially underwent electrocardiography, echocardiography, extracranial and lower limb Doppler ultrasound, and laboratory tests (complete blood count, biochemical blood tests, lipid profile). Three medical organizations of the Moscow State Healthcare System participate in the study.Results. Interim data are presented to evaluate the effectiveness of PCSK9 targeted therapy in patients with ASCVD, obtained 3 months from the study start. The comparison groups were comparable in main clinical characteristics. When analyzing the lipid-lowering effect of inclisiran in the examined patients with ASCVD, LDL-C level significantly decreased from 2,53±0,10 mmol/l to 110±0,08 mmol/l (by 56,5%), p<0,0001, while the target LDL-C level <1,4 mmol/l was achieved by 77,5% of the subjects. Analysis of the lipid-lowering effect of alirocumab/evolocumab showed a significant LDL-C decrease from 2,48±0,16 mmol/l to 1,07±0,11 mmol/l (by 56,8%), p<0,0001.Conclusion. The use of PCSK9 targeted therapy (alirocumab or inclisiran or evolocumab) in patients with ASCVD in Moscow make it possible to achieve target LDL-C levels, which are indicated in clinical guidelines, by 3 months.https://russjcardiol.elpub.ru/jour/article/view/5687atherosclerosisinclisiranpcsk9 inhibitors |
| spellingShingle | A. I. Sapina Yu. Yu. Varlamova M. G. Papyrina A. S. Bezymyannyy E. Yu. Vasilyeva Observational study of inclisiran effectiveness in Moscow healthcare Российский кардиологический журнал atherosclerosis inclisiran pcsk9 inhibitors |
| title | Observational study of inclisiran effectiveness in Moscow healthcare |
| title_full | Observational study of inclisiran effectiveness in Moscow healthcare |
| title_fullStr | Observational study of inclisiran effectiveness in Moscow healthcare |
| title_full_unstemmed | Observational study of inclisiran effectiveness in Moscow healthcare |
| title_short | Observational study of inclisiran effectiveness in Moscow healthcare |
| title_sort | observational study of inclisiran effectiveness in moscow healthcare |
| topic | atherosclerosis inclisiran pcsk9 inhibitors |
| url | https://russjcardiol.elpub.ru/jour/article/view/5687 |
| work_keys_str_mv | AT aisapina observationalstudyofinclisiraneffectivenessinmoscowhealthcare AT yuyuvarlamova observationalstudyofinclisiraneffectivenessinmoscowhealthcare AT mgpapyrina observationalstudyofinclisiraneffectivenessinmoscowhealthcare AT asbezymyannyy observationalstudyofinclisiraneffectivenessinmoscowhealthcare AT eyuvasilyeva observationalstudyofinclisiraneffectivenessinmoscowhealthcare |